Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Arthritis Care Res (Hoboken). 2016 Jun;68(6):753–762. doi: 10.1002/acr.22752

Table 3.

Hazard ratios for total mortality for women with RA by serologic phenotype compared to women without RA in the Nurses’ Health Study (1976–2012)*

Deaths Person-years Mortality rate Age-adjusted HR (95% CI) Multivariable HR (95% CI)
All RA
 No RA 28,501 3,678,801 775 1.00 (reference) 1.00 (reference)
 RA 307 17,983 1,707 1.45 (1.30–1.63) 1.40 (1.25–1.57)
Seropositive RA
 No RA 28,492 3,425,924 832 1.00 (reference) 1.00 (reference)
 RA 202 10,869 1,858 1.59 (1.38–1.82) 1.51 (1.31–1.74)
Seronegative RA
 No RA 28,501 3,666,676 777 1.00 (reference) 1.00 (reference)
 RA 105 7,113 1,476 1.18 (0.97–1.43) 1.15 (0.95–1.39)
*

RA = rheumatoid arthritis; HR = hazard ratio; 95% CI = 95% confidence interval.

Per 100,000 person-years.

Model adjusted for age, questionnaire cycle, census-tract family income (<$40,000 or ≥$40,000 per year), body mass index (<18.5, 18.5–24.9, 25–29.9, or ≥30 kg/m2), cigarette smoking (never–10, 10.1–20, or >20 pack-years), postmenopausal hormone use (premenopausal, postmenopausal: never postmenopausal hormone use, postmenopausal: past postmenopausal hormone use, or postmenopausal: current postmenopausal hormone use), moderate to vigorous physical activity (0, 0.01–0.99, 1.00–3.49, 3.50–5.99, or ≥6 hours per week), cumulative average of Alternate Healthy Eating Index excluding alcohol component (quintiles), alcohol consumption (0, 0.1–4.9, 5.0–14.9, or ≥15.0 gm/day), cardiovascular disease (yes/no), and aspirin use (yes/no). Covariates were updated up to death, end of study period, censor, or loss to follow-up, whichever came first.